As in the previous quarter, the 2013 half-year sales recorded by Nanobiotix
corresponds to the pro-rata share of the upfront payment received by the Company
in August 2012, within the framework of the licensing contract signed with the
Taiwanese company, PharmaEngine for the development and marketing of NBTXR3 in
the Asia-Pacific region.
This upfront payment amounts to €811k generating a revenue of €92k for the first
semester of 2013. The invoicing of services totalled €3k for the period. In
total, revenue for the first half of 2013 is €95k which is fully in line with
Total revenue also includes subsidies and research tax credits. The amount of
research tax credits has risen due to the increased spending in R&D reflecting
our activity in clinical studies amounting €572k.
Operational costs are amounting €5.0m compared to €3.0m as of June, 30(th) 2012.
R&D costs have risen as expected with the strengthening of clinical studies for
our lead product NBTXR3 in the STS indication and the preparation of new
indications such as head and neck. Some recruitment has been done to enhance the
operational and scientific skills within the Company.
General costs have increased due some expected expenses following Company's new
listed status and due to the reinforcement of the Company's governance
The core operating loss was €4.3m compared to €2.5m in H1 2012. The total net
loss amounted to €4.3m (HY1 2012: €2.5m).
The cash balance has been carefully managed during the period and as at 30 June
2013, was €8.1m (HY1 2012: €1.0m) as per the forecast stated during the IPO, in
order to support company's development plan.
Laurent Levy, CEO of Nanobiotix, will host a conference call for analysts to
provide an overview on Nanobiotix and the Half Year results, followed by a Q&A
session, in the morning on Monday, 2 September 2013.
If you would like further information, please contact College Hill: +44 (0)
207 457 2020.
Next financial press release: revenue for the 3(rd) quarter of 2013 on November
Nanobiotix is a clinical-stage nanomedicine company pioneering novel approaches
for the local treatment of cancer. The Company's first-in-class, proprietary
technology, NanoXray, enhances radiotherapy energy to provide a new, more
efficient treatment for cancer patients. NanoXray products are compatible with
current radiotherapy and brachytherapy treatments and are meant to treat a wide
variety of cancers via multiple routes of administration. Nanobiotix's lead
product NBTXR3, based on NanoXray, is currently under clinical development for
soft tissue sarcoma. The Company has partnered with PharmaEngine for clinical
development and commercialization of NBTXR3 in Asia. The Company is based in
Nanobiotix is listed on the NYSE Euronext regulated market in Paris (ISIN:
FR0011341205, Euronext ticker: NANO, Bloomberg: NANO: FP).
For more information, please contact:
Sarah Gaubert Media relations (France)
Head of Communication and public Annie-Florence Loyer / NadÈge Le Lezec
+33 (0)1 40 26 07 55
firstname.lastname@example.org +33 (0)1 53 63 27 27 / +33 (0)6
88 20 35 59
NewCap. College Hill
Financial communication and investors Media relations (Outside France)
relations Melanie Toyne Sewell / Claire Dickinson
Louis-Victor Delouvrier / Emmanuel +44 (0) 207 457 2020
+33 (0)1 44 71 98 53
Press Release (PDF):
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: NANOBIOTIX via Thomson Reuters ONE